195 related articles for article (PubMed ID: 38313835)
1. Efficacy and safety of insulin glargine 300 units/mL vs insulin degludec in patients with type 1 and type 2 diabetes: a systematic review and meta-analysis.
Alhmoud EN; Saad MO; Omar NE
Front Endocrinol (Lausanne); 2023; 14():1285147. PubMed ID: 38313835
[TBL] [Abstract][Full Text] [Related]
2. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
[TBL] [Abstract][Full Text] [Related]
3. (Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus.
Hemmingsen B; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013498. PubMed ID: 33662147
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of basal insulins in people with type 2 diabetes mellitus: a systematic review and network meta-analysis of randomized clinical trials.
Dehghani M; Sadeghi M; Barzkar F; Maghsoomi Z; Janani L; Motevalian SA; Loke YK; Ismail-Beigi F; Baradaran HR; Khamseh ME
Front Endocrinol (Lausanne); 2024; 15():1286827. PubMed ID: 38586456
[TBL] [Abstract][Full Text] [Related]
5. Reduced risk of hypoglycemia with insulin degludec versus insulin glargine in patients with type 2 diabetes requiring high doses of basal insulin: a meta-analysis of 5 randomized begin trials.
Rodbard HW; Gough S; Lane W; Korsholm L; Bretler DM; Handelsman Y
Endocr Pract; 2014 Apr; 20(4):285-92. PubMed ID: 24246344
[TBL] [Abstract][Full Text] [Related]
6. Clinical perspectives from the BEGIN and EDITION programmes: Trial-level meta-analyses outcomes with either degludec or glargine 300U/mL vs glargine 100U/mL in T2DM.
Roussel R; Ritzel R; Boëlle-Le Corfec E; Balkau B; Rosenstock J
Diabetes Metab; 2018 Nov; 44(5):402-409. PubMed ID: 29548798
[TBL] [Abstract][Full Text] [Related]
7. A Multinational, Randomized, Open-label, Treat-to-Target Trial Comparing Insulin Degludec and Insulin Glargine in Insulin-Naïve Patients with Type 2 Diabetes Mellitus.
Pan C; Gross JL; Yang W; Lv X; Sun L; Hansen CT; Xu H; Wagner R
Drugs R D; 2016 Jun; 16(2):239-49. PubMed ID: 27098525
[TBL] [Abstract][Full Text] [Related]
8. Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial.
Wysham C; Bhargava A; Chaykin L; de la Rosa R; Handelsman Y; Troelsen LN; Kvist K; Norwood P
JAMA; 2017 Jul; 318(1):45-56. PubMed ID: 28672317
[TBL] [Abstract][Full Text] [Related]
9. Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial.
Lingvay I; Pérez Manghi F; García-Hernández P; Norwood P; Lehmann L; Tarp-Johansen MJ; Buse JB;
JAMA; 2016 Mar; 315(9):898-907. PubMed ID: 26934259
[TBL] [Abstract][Full Text] [Related]
10. Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial.
Gough SC; Bhargava A; Jain R; Mersebach H; Rasmussen S; Bergenstal RM
Diabetes Care; 2013 Sep; 36(9):2536-42. PubMed ID: 23715753
[TBL] [Abstract][Full Text] [Related]
11. Insulin Degludec Versus Insulin Glargine on Glycemic Variability in Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Yang Y; Long C; Li T; Chen Q
Front Endocrinol (Lausanne); 2022; 13():890090. PubMed ID: 35721710
[TBL] [Abstract][Full Text] [Related]
12. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Lo C; Toyama T; Oshima M; Jun M; Chin KL; Hawley CM; Zoungas S
Cochrane Database Syst Rev; 2020 Jul; 8(8):CD009966. PubMed ID: 32803882
[TBL] [Abstract][Full Text] [Related]
13. Comparative safety and efficacy of insulin degludec with insulin glargine in type 2 and type 1 diabetes: a meta-analysis of randomized controlled trials.
Zhang XW; Zhang XL; Xu B; Kang LN
Acta Diabetol; 2018 May; 55(5):429-441. PubMed ID: 29423761
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Tolerability of Insulin Degludec Versus Other Long-acting Basal Insulin Analogues in the Treatment of Type 1 and Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis.
Dong ZY; Feng JH; Zhang JF
Clin Ther; 2022 Nov; 44(11):1520-1533. PubMed ID: 36763996
[TBL] [Abstract][Full Text] [Related]
15. Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes: The SWITCH 1 Randomized Clinical Trial.
Lane W; Bailey TS; Gerety G; Gumprecht J; Philis-Tsimikas A; Hansen CT; Nielsen TSS; Warren M; ;
JAMA; 2017 Jul; 318(1):33-44. PubMed ID: 28672316
[TBL] [Abstract][Full Text] [Related]
16. Insulin degludec results in lower rates of nocturnal hypoglycaemia and fasting plasma glucose vs. insulin glargine: A meta-analysis of seven clinical trials.
Russell-Jones D; Gall MA; Niemeyer M; Diamant M; Del Prato S
Nutr Metab Cardiovasc Dis; 2015 Oct; 25(10):898-905. PubMed ID: 26232910
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety among second-generation and other basal insulins in adult patients with type 1 diabetes: a systematic review and network meta-analysis.
Martin ; Zhou Y; Takagi T; Tian YS
Naunyn Schmiedebergs Arch Pharmacol; 2021 Oct; 394(10):2091-2101. PubMed ID: 34319421
[TBL] [Abstract][Full Text] [Related]
18. Comparative efficiency and safety of insulin degludec/aspart with insulin glargine in type 2 diabetes: a meta-analysis of randomized controlled trials.
Long T; Lin JT; Lin MH; Wu QL; Lai JM; Li SZ; Zhou ZC; Zeng JY; Huang JS; Zeng CP; Lai YM
Endocr J; 2022 Aug; 69(8):959-969. PubMed ID: 35431280
[TBL] [Abstract][Full Text] [Related]
19. PATIENTS ACHIEVING GOOD GLYCEMIC CONTROL (HBA1c <7%) EXPERIENCE A LOWER RATE OF HYPOGLYCEMIA WITH INSULIN DEGLUDEC THAN WITH INSULIN GLARGINE: A META-ANALYSIS OF PHASE 3A TRIALS.
Einhorn D; Handelsman Y; Bode BW; Endahl LA; Mersebach H; King AB
Endocr Pract; 2015 Aug; 21(8):917-26. PubMed ID: 26121451
[TBL] [Abstract][Full Text] [Related]
20. More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial.
Rosenstock J; Cheng A; Ritzel R; Bosnyak Z; Devisme C; Cali AMG; Sieber J; Stella P; Wang X; Frías JP; Roussel R; Bolli GB
Diabetes Care; 2018 Oct; 41(10):2147-2154. PubMed ID: 30104294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
